US FDA studying diabetes and CV risks with prostate cancer drugs
This article was originally published in Scrip
Executive Summary
The US FDA is investigating a potential risk of diabetes and cardiovascular complications for prostate cancer patients treated with gonadotropin-releasing hormone (GnRH) agonists.